Imagine battling a devastating brain disorder that robs people of their personalities and abilities long before their time—frontotemporal dementia (FTD), a lesser-known cousin of Alzheimer's, affects thousands with symptoms like behavioral changes and language loss. But what if collaboration could turn the tide? That's the bold promise of the 2025 FTD Research Roundtable, where experts gathered to tackle the hurdles in developing treatments that could actually slow or stop this disease. And this is the part most people miss: it's not just about science; it's about uniting voices to make clinical trials smarter and more effective. But here's where it gets controversial: as we push for data sharing, are we risking personal privacy in the name of progress?
In September, the Association for Frontotemporal Degeneration (AFTD) hosted its third annual FTD Research Roundtable (accessible at https://www.theaftd.org/for-researchers/ftsg/), a vital gathering that assembles a wide array of participants. This year's focus was on 'outcome measures and statistical power in FTD clinical trials'—essentially, the tools and methods we use to prove if a new therapy truly works, like measuring how well it slows down symptoms or improves quality of life. For beginners curious about FTD, think of it as a group of brain cells in the front and sides of the head that start misfiring, leading to changes in behavior, emotions, and communication. Disease-modifying therapies aim to fix or halt these underlying issues, not just mask symptoms, making them a game-changer for patients and families.
This roundtable isn't AFTD's only strategy for boosting clinical trials (check out their full plan at https://www.theaftd.org/our-plan-goal-one/). Trials face real-world obstacles, such as recruiting enough eligible people from a small pool of those affected by FTD, figuring out the best ways to define who qualifies for a study, tracking how the disease advances, assessing a drug's effects, and overcoming practical hurdles like funding, logistics, and varying resources at different research sites. To put it simply, imagine trying to test a new drug on a rare condition—it's like finding a needle in a haystack, but with lives depending on it.
This year's event drew an impressive crowd of 87 attendees, including 12 pharmaceutical companies at different stages of developing FTD drugs, four nonprofit groups like AFTD, academic researchers, industry experts, regulators from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), individuals with personal experience of FTD, and AFTD's own board members and staff. Leadership came from Academic Co-Chair Jonathan Rohrer, MD, PhD, from University College London, and Industry Co-Chair Arthur Simen, MD, PhD, from Johnson & Johnson (formerly at Takeda Pharmaceuticals), who crafted the agenda (detailed at https://www.theaftd.org/research-roundtable-2025/) alongside a larger committee featuring Dr. Michelle Campbell from the FDA and Dr. Steffen Thirstrup from the EMA.
Key takeaways from the discussions sparkled with innovation and insight. For instance, efforts are underway to align outcome assessments from major studies like ALLFTD and GENFI, which could lead to better ways of monitoring how FTD progresses over time—think of it as creating a unified roadmap that helps researchers spot improvements more accurately. Another exciting development: validated remote assessment tools, usable from home, are being refined to complement in-person checks, making trials more accessible and less burdensome for participants. This could mean fewer trips to clinics, which is huge for those with mobility issues. Plus, incorporating more qualitative insights—stories and experiences from people living with FTD—can help regulators grasp the real-world impact of trial results, ensuring outcomes aren't just numbers but meaningful changes in daily life.
Properly leveraging existing data from natural history studies (long-term observations of how FTD unfolds without treatment) holds potential to streamline trials by needing fewer participants, reducing clinic visits, and limiting exposure to placebos. Since FTD is rarer than Alzheimer's, a common stumbling block is sourcing clinical data and biological samples for new studies. Instead of every group reinventing the wheel and overwhelming participants, the question looms: how can we maximize data sharing for collective benefit? And this is where controversy brews—while sharing could accelerate discoveries, it raises debates about data security, consent, and whether big pharma's involvement might prioritize profits over open science. Is this a necessary trade-off, or could it lead to unintended ethical dilemmas?
AFTD is actively pursuing solutions to these puzzles and extends heartfelt gratitude to everyone impacted by FTD who've contributed to research, from broad natural history studies to targeted ones. Your involvement fuels the data that drives real progress, helping scientists inch closer to breakthroughs.
Eager to get involved? Explore the FTD Disorders Registry at https://www.ftdregistry.org/ for ways to participate in research.
What are your thoughts? Do you believe that pushing for more data sharing in medical research is worth potential privacy risks, or should we be more cautious? And how do you feel about pharmaceutical companies leading the charge—does it inspire confidence or raise red flags? Share your opinions in the comments below; let's discuss!
